SRB22(SRB22) - 药物靶点：HER3_在研适应症：肿瘤_专利_临床

概要

基本信息

药物类型

抗体

别名

靶点

HER3

作用机制

HER3调节剂(受体酪氨酸蛋白激酶erbB-3调节剂)

治疗领域

肿瘤

在研适应症

肿瘤

非在研适应症-

原研机构

Sunrock Biopharma SL初创企业

在研机构

Sunrock Biopharma SL初创企业

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 SRB22 相关的临床结果

登录后查看更多信息

100 项与 SRB22 相关的转化医学

登录后查看更多信息

100 项与 SRB22 相关的专利（医药）

登录后查看更多信息

1

项与 SRB22 相关的文献（医药）

Marine Drugs2区 · 医学

A Marine Sulfate-Reducing Bacterium Producing Multiple Antibiotics: Biological and Chemical Investigation

2区 · 医学

ArticleOA

作者: Gu, Xiaojie ; Zhang, Yi ; Mu, Jun ; Zhao, Chenyan ; Xie, Zeping ; Wang, Xiaoliang

A marine sulfate-reducing bacterium SRB-22 was isolated by means of the agar shake dilution method and identified as Desulfovibrio desulfuricans by morphological, physiological and biochemical characteristics and 16S rDNA analysis. In the bioassay, its extract showed broad-spectrum antimicrobial activity using the paper disc agar diffusion method. This isolate showed a different antimicrobial profile than either ampicillin or nystatin and was found to produce at least eight antimicrobial components by bioautography. Suitable fermentation conditions for production of the active constituents were determined to be 28 day cultivation at 25 °C to 30 °C with a 10% inoculation ratio. Under these conditions, the SRB-22 was fermented, extracted and chemically investigated. So far an antimicrobial compound, mono-n-butyl phthalate, and an inactive compound, thymine, have been isolated and characterized.

100 项与 SRB22 相关的药物交易

登录后查看更多信息